Acquired Company
Neoleukin Therapeutics was acquired by Neurogene Inc. in an all-stock merger that closed on December 18, 2023, with Neurogene becoming the surviving company.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. Show more
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$21.51
Open
$21.60
Volume
93,513
Day Range
$21.27 - $22.13
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
09/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
NL-201 (IL-2 and IL-15 agonist) Details Solid tumor/s, Cancer | Failed Discontinued |